Hyperactive androgen receptor in prostate cancer: What does it mean for new therapy concepts?

Histology and Histopathology

Volumn 12, Issue 3, 1997, Pages 781-786

  Culig, Z ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor activation; Antiandrogens; Prostate tumor metastases; Steroids

Indexed keywords

ANDROGEN RECEPTOR; GROWTH FACTOR; PEPTIDE;

ANDROGEN RELEASE; ANIMAL CELL; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MALE; METASTASIS; NONHUMAN; POINT MUTATION; PROSTATE CARCINOMA; RAT; RECEPTOR UPREGULATION; REVIEW; SECOND MESSENGER;

ANIMALS; GROWTH SUBSTANCES; HUMANS; MALE; POINT MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0030741380     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Borring C.C., Squires T.S. and Tong T. (1993). Cancer statistics 1993. CA Cancer J. Clin. 43, 7-26.
2. Brass A.L., Barnard J., Patai B.L. Salvi D. and Rukstalis D.B. (1995). Androgen up-regulates epidermal growth factor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res. 55, 3197-3203.
3. Bubley G., Fenton M., Fertig A., DeWolf W., Shuster T. and Balk S. (1996). The hormonal sensitivity of androgen receptor (AR) mutations derived from human tumors. Cancer Res. 37,1680A.
4. Castagnaro M., Yandell D.W., Dockhorn Dworniczak B., Wolfe H. and Poremba C. (1993). Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh. Dtsch. Ges. Pathol. 77, 119-123.
5. Chamberlain N.C., Driver E.D. and Miesfeld R.L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186.
6. Crawford E.D., Blumenstein B.A., Goodman P.J., Davis M.A., Eisenberger M.A., McLeod M.G., Spaulding J.T., Benson R. and Dorr F.A. (1990). Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66,1039-1044.